Product label
Regulatory context; not efficacy evidence
People meeting the current Imcivree diagnostic and age criteria; see the current label.
Reported findings. Imcivree has FDA-approved labeled indications.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Label warns of depression/suicidal ideation, hypersensitivity, sexual-arousal and pigmentary effects.
Limits. Approval is specific to Imcivree and its eligible populations, not general weight loss or research vials.
Preparation: Imcivree labeled setmelanotide Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.